Published by Josh White on 2nd April 2024
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.
URL: http://www.digitallook.com/dl/news/story/34193163/...